To date, pure-tone audiometry remains the gold standard for clinical auditory testing. However, pure-tone audiometry is time-consuming and only provides a discrete estimate of hearing acuity. Here, we aim to address these two main drawbacks by developing a machine learning (ML)-based approach for fully automated bone-conduction (BC) audiometry tests with forehead vibrator placement. Study 1 examines the occlusion effects when the headphones are positioned on both ears during BC forehead testing. Study 2 describes the ML-based approach for BC audiometry, with automated contralateral masking rules, compensation for occlusion effects and forehead-mastoid corrections. Next, the performance of ML-audiometry is examined in comparison to manual and conventional BC audiometry with mastoid placement. Finally, Study 3 examines the test-retest reliability of ML-audiometry. Our results show no significant performance difference between automated ML-audiometry and manual conventional audiometry. High test-retest reliability is achieved with the automated ML-audiometry. Together, our findings demonstrate the performance and reliability of the automated ML-based BC audiometry for both normal-hearing and hearing-impaired adult listeners with mild to severe hearing losses.

Download full-text PDF

Source
http://dx.doi.org/10.1177/23312165241286456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703668PMC

Publication Analysis

Top Keywords

performance reliability
8
automated bone-conduction
8
audiometry
8
bone-conduction audiometry
8
machine learning
8
pure-tone audiometry
8
ml-based approach
8
study examines
8
occlusion effects
8
manual conventional
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.

Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with neuroinflammation and heightened production of reactive oxygen species (ROS) in the brain from overactive NADPH Oxidase 2 (NOX2). The current study examines whether administration of a novel, brain-penetrant NOX2 inhibitor (CPP11G & CPP11H) reduces amyloid plaque load and improves AD-associated vascular dysfunction in a male APP-PS1 mouse model of AD.

Method: Intraperitoneal injections of CPP11G (n = 1) or CPP11H (n = 2) three times per week began at 9-10 months of age in the treatment APP-PS1 group (15 mg/kg).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Pentara Corporation, Salt Lake City, UT, USA.

Background: Alzheimer's disease (AD) clinical trials led to the recent successes with monoclonal antibodies targeting amyloid, which opens up many new directions for research into treatment for AD in the future. Gaining greater understanding from these successes and failures will help researchers to focus their efforts on avenues that have the highest potential benefit.

Method: We performed a meta-analysis of over a hundred studies of 70+ AD treatments.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Deakin University, Geelong, VIC, Australia.

Background: Reliable treatment approaches for addressing early cognitive impairment and Alzheimer's disease (AD) are currently lacking. Given the multifactorial nature of AD, therapeutic strategies need to focus on disease-specific biochemical pathways. Given the significance of metabolic pathways in cognitive impairment, it is essential to investigate alternative disease modifiers capable of targeting multiple metabolic pathways, such as phytochemicals.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Siemens Heathineers, Princeton, NJ, USA.

Background: The recent breakthrough in monoclonal antibody treatment for Alzheimer's disease (AD) has ushered in a new phase in AD healthcare. However, associated amyloid-related imaging abnormalities (ARIA) present a significant risk to patients, necessitating careful monitoring. Detection by radiologists can be challenging and may suffer from inconsistency.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!